question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
25,2026-02-01,Structured Query,Which human enzymes are involved in NADH-dependent biochemical reactions?,True,True,False,0.42857142857142855,"NADH (the reduced form of NAD+) serves as an electron donor in numerous biochemical reactions. Here are the major classes of human enzymes that utilize NADH:

## 1. **Dehydrogenases**
These are the primary NADH-dependent enzymes:

### Glycolysis & Gluconeogenesis
- **Glyceraldehyde-3-phosphate dehydrogenase** (uses NAD+, produces NADH)
- **Lactate dehydrogenase (LDH)** - converts pyruvate to lactate (oxidizes NADH to NAD+)

### Citric Acid Cycle
- **Malate dehydrogenase** - converts malate to oxaloacetate
- **Isocitrate dehydrogenase** (NAD+-dependent form)
- **α-ketoglutarate dehydrogenase complex**

### Amino Acid Metabolism
- **Glutamate dehydrogenase** - involved in amino acid catabolism
- **Branched-chain α-keto acid dehydrogenase**

### Lipid Metabolism
- **3-hydroxyacyl-CoA dehydrogenase** - β-oxidation of fatty acids
- **HMG-CoA reductase** (uses NADPH primarily, but related pathway)

## 2. **Electron Transport Chain Complexes**
- **Complex I (NADH dehydrogenase/NADH-CoQ reductase)** - the primary site where NADH donates electrons to the respiratory chain

## 3. **Other Enzymes**
- **Alcohol dehydrogenase** - ethanol metabolism
- **Aldehyde dehydrogenases** - various aldehyde detoxification
- **Dihydrofolate reductase** - folate metabolism (primarily NADPH-dependent)

These enzymes are critical for energy metabolism, biosynthesis, and maintaining cellular redox balance.",,8.738549709320068,53,468,True,True,0.5,"Based on my search of biological databases, I can provide you with a comprehensive overview of human enzymes involved in NADH-dependent biochemical reactions:

## Major Classes of Human NADH-Dependent Enzymes

### 1. **NADH Dehydrogenase Complex (Complex I)**
The mitochondrial respiratory chain Complex I is the primary consumer of NADH:
- **NDUFV1** and **NDUFV2** - Flavoprotein subunits (EC 7.1.1.2)
- Multiple structural subunits (NDUFA1-13, NDUFB1-11, NDUFC1-2, NDUFS1-8)
- Function: Oxidizes NADH and transfers electrons to ubiquinone

### 2. **Lactate Dehydrogenase (LDH)**
- **LDH-A** (P00338) - Muscle subunit (EC 1.1.1.27)
- **LDH-B** (P07195) - Heart subunit (EC 1.1.1.27)
- **LDH-C** (P07864) - Testis subunit (EC 1.1.1.27)
- Function: Interconverts pyruvate and lactate using NADH/NAD+

### 3. **Malate Dehydrogenase (MDH)**
- **MDH1** (P40925) - Cytoplasmic (EC 1.1.1.37)
- **MDH2** (P40926) - Mitochondrial (EC 1.1.1.37)
- Function: Converts malate to oxaloacetate in TCA cycle and gluconeogenesis

### 4. **Alcohol Dehydrogenases (ADH)**
- **ADH1A, ADH1B, ADH1C** - Class I (EC 1.1.1.1)
- **ADH4** - Class II (EC 1.1.1.105)
- **ADH5** - Class III (EC 1.1.1.1)
- **ADH6** and **ADH7** (EC 1.1.1.1, EC 1.1.1.105)
- Function: Oxidize alcohols to aldehydes/ketones

### 5. **Glutamate Dehydrogenase**
- **GLUD1** (P00367) - GDH1 (EC 1.4.1.3)
- **GLUD2** (P49448) - GDH2 (EC 1.4.1.3)
- Function: Reversibly converts glutamate to α-ketoglutarate

### 6. **Aldehyde Dehydrogenases (ALDH)**
- **ALDH1A1** (P00352) - Cytosolic (EC 1.2.1.3)
- **ALDH7A1** (P49419) - α-aminoadipic semialdehyde dehydrogenase
- **ALDH4A1** (P30038) - Δ1-pyrroline-5-carboxylate dehydrogenase
- **ALDH5A1** (P51649) - Succinate-semialdehyde dehydrogenase
- Function: Oxidize aldehydes to carboxylic acids

### 7. **Cytochrome b5 Reductases**
- **CYB5R1, CYB5R2, CYB5R3** (EC 1.6.2.2)
- Function: Reduce cytochrome b5 using NADH as electron donor

### 8. **Isocitrate Dehydrogenase (NAD+-dependent)**
- **IDH3A** (P50213) - α subunit (EC 1.1.1.41)
- **IDH3B** (O43837) - β subunit
- **IDH3G** (P51553) - γ subunit
- Function: TCA cycle enzyme (oxidizes isocitrate to α-ketoglutarate)

### 9. **3-Hydroxyacyl-CoA Dehydrogenases**
- **HADH** (Q16836) - Short-chain (EC 1.1.1.35)
- Function: β-oxidation of fatty acids

### 10. **Glycerol-3-Phosphate Dehydrogenase**
- Function: Converts glycerol-3-phosphate to DHAP (Rhea reaction: RHEA:11092)

## Key Biochemical Reactions

From the Rhea database, NADH participates in reactions including:
- **Electron transport**: Ubiquinone reduction (RHEA:23152)
- **Detoxification**: H₂O₂ reduction (RHEA:18509)
- **Metabolism**: Numerous oxidation-reduction reactions in glycolysis, TCA cycle, fatty acid oxidation
- **Biosynthesis**: Steroid and lipid metabolism
- **Xenobiotic metabolism**: Hydroxylation reactions

These enzymes are crucial for:
- Energy production (ATP synthesis via oxidative phosphorylation)
- Metabolic homeostasis
- Biosynthetic pathways
- Detoxification processes
- Redox balance",,59.46197295188904,24,2282,39966,96376,"mcp__togomcp__search_rhea_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity","[{""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""NADH"", ""limit"": 100}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""NADH dehydrogenase human"", ""limit"": 20}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?protein ?name ?ecNumber WHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:enzyme ?enzyme ;\n           up:recommendedName ?recName .\n  ?recName up:fullName ?name .\n  ?enzyme up:activity ?activity .\n  ?activity up:ecName ?ecNumber .\n  \n  FILTER(CONTAINS(LCASE(?name), \""dehydrogenase\"") || CONTAINS(LCASE(?name), \""reductase\""))\n  FILTER(REGEX(?name, \""NAD\"", \""i\"") || REGEX(STR(?activity), \""NAD\"", \""i\""))\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""alcohol dehydrogenase human"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""malate dehydrogenase human"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""glutamate dehydrogenase human"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""glucose-6-phosphate dehydrogenase human"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""isocitrate dehydrogenase human"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""cytochrome b5 reductase human"", ""limit"": 10}}]",CRITICAL,"List of human enzymes that catalyze reactions using NADH as cofactor, with their UniProt IDs and reaction equations","COMPLEX QUERY requiring cross-database and compound knowledge.

Databases/Resources: UniProt, Rhea, ChEBI

Knowledge Required:
- ChEBI compound linkage (NADH: CHEBI:57945)
- Compound-to-reaction path via rdfs:subClassOf in Rhea
- Cross-database join via EC numbers
- up:reviewed 1 filter essential
- Multiple GRAPH clauses on shared SIB endpoint

Without proper knowledge: Cannot identify compound-reaction relationships or query times out.

Verified in rhea_exploration.md Pattern 3 (Compound-Specific Reaction Discovery)."
26,2026-02-01,Structured Query,What are the protein-coding genes on human chromosome 17 in Ensembl?,True,False,True,0.7777777777777778,"I don't have access to a complete, current list of all protein-coding genes on human chromosome 17 from Ensembl in my training data. However, I can tell you some general information:

**Key facts about chromosome 17:**
- It's a medium-sized chromosome containing approximately 1,200-1,400 genes total
- Roughly 800-900 of these are protein-coding genes
- It represents about 2.5% of the human genome

**Some well-known protein-coding genes on chromosome 17 include:**
- **TP53** - the tumor suppressor gene (p53)
- **BRCA1** - breast cancer susceptibility gene
- **NF1** - neurofibromin 1
- **ERBB2** (HER2) - receptor tyrosine kinase
- **MAP2K4** - mitogen-activated protein kinase kinase 4
- **NGFR** - nerve growth factor receptor
- **SLC6A4** - serotonin transporter
- **RARA** - retinoic acid receptor alpha

**To get the complete current list, you would need to:**
1. Visit the Ensembl website (ensembl.org)
2. Search for ""Chromosome 17"" or navigate to the human genome browser
3. Use BioMart or the chromosome view to filter for protein-coding genes specifically

The exact number and annotations are regularly updated with each Ensembl release as genome annotation improves.",,8.11679983139038,56,345,True,True,0.7777777777777778,"Perfect! I now have detailed information about protein-coding genes on human chromosome 17. Let me provide you with a comprehensive summary:

## Protein-Coding Genes on Human Chromosome 17

According to **NCBI Gene database**, there are **1,181 protein-coding genes** located on human chromosome 17.

### Notable Examples (from the first 20 genes):

Here are some of the most well-known and medically important genes on chromosome 17:

1. **TP53** (17p13.1) - Tumor protein p53, a crucial tumor suppressor involved in cell cycle regulation and apoptosis. Mutations are associated with Li-Fraumeni syndrome and many cancers.

2. **BRCA1** (17q21.31) - Breast cancer 1, DNA repair associated. Responsible for ~40% of inherited breast cancers and >80% of inherited breast and ovarian cancers.

3. **ERBB2/HER2** (17q12) - Erb-b2 receptor tyrosine kinase 2. Often amplified in breast and ovarian cancers and is a major therapeutic target.

4. **NF1** (17q11.2) - Neurofibromin 1. Mutations cause neurofibromatosis type 1.

5. **STAT3** (17q21.2) - Signal transducer and activator of transcription 3. Key role in cell growth, apoptosis, and immune response.

6. **MAPT** (17q21.31) - Microtubule-associated protein tau. Associated with Alzheimer's disease, Pick's disease, and other neurodegenerative disorders.

7. **ACE** (17q23.3) - Angiotensin I converting enzyme. Critical for blood pressure regulation and target of ACE inhibitors.

8. **SLC6A4** (17q11.2) - Serotonin transporter. Involved in depression and anxiety disorders.

9. **CCL2** and **CCL5** - Chemokine ligands involved in immune response and inflammation.

10. **COL1A1** (17q21.33) - Collagen type I alpha 1 chain. Mutations associated with osteogenesis imperfecta and Ehlers-Danlos syndrome.

The genes span across all arms of chromosome 17 (from 17p to 17q) and are involved in diverse biological processes including cancer, neurodegenerative diseases, immune function, cardiovascular regulation, and structural proteins.",,75.7992160320282,43,2134,37384,216696,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""ensembl"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX dc: <http://purl.org/dc/terms/>\n\nSELECT DISTINCT ?gene ?label\nWHERE {\n  ?gene a ?type .\n  ?gene obo:SO_0000110 ?chromosome .\n  ?gene rdfs:label ?label .\n  \n  # Filter for protein-coding genes\n  FILTER(?type = obo:SO_0001217)\n  \n  # Filter for chromosome 17\n  FILTER(CONTAINS(STR(?chromosome), \""chromosome:GRCh38:17:\""))\n}\nORDER BY ?label\nLIMIT 1000\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""ensembl"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX dc: <http://purl.org/dc/terms/>\nPREFIX ensembl: <http://rdf.ebi.ac.uk/resource/ensembl/>\nPREFIX term: <http://rdf.ebi.ac.uk/terms/ensembl/>\n\nSELECT DISTINCT ?gene ?label\nWHERE {\n  ?gene a term:protein_coding .\n  ?gene term:has_location ?location .\n  ?location term:has_region ?region .\n  ?gene rdfs:label ?label .\n  \n  FILTER(CONTAINS(STR(?region), \"":17:\""))\n}\nORDER BY ?label\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""ensembl"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?type (COUNT(?s) as ?count)\nWHERE {\n  ?s a ?type .\n}\nGROUP BY ?type\nORDER BY DESC(?count)\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""ensembl"", ""sparql_query"": ""\nSELECT ?s ?p ?o\nWHERE {\n  ?s ?p ?o .\n  FILTER(CONTAINS(STR(?s), \""ENSG\""))\n}\nLIMIT 10\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""ensembl"", ""sparql_query"": ""\nPREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX faldo: <http://biohackathon.org/resource/faldo#>\n\nSELECT DISTINCT ?gene ?start ?end\nWHERE {\n  ?gene a obo:SO_0001217 .\n  ?gene faldo:location ?location .\n  ?location faldo:begin ?beginPos .\n  ?location faldo:end ?endPos .\n  ?beginPos faldo:position ?start .\n  ?beginPos faldo:reference ?chr .\n  ?endPos faldo:position ?end .\n  \n  FILTER(CONTAINS(STR(?chr), \"":17:\""))\n}\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""Homo sapiens[Organism] AND 17[Chromosome] AND alive[property] AND genetype protein coding[Properties]"", ""max_results"": 100}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""7157"", ""2064"", ""6774"", ""672"", ""1636"", ""4137"", ""6532"", ""6347"", ""332"", ""3690"", ""1277"", ""4843"", ""5578"", ""6352"", ""4353"", ""4763"", ""2896"", ""8678"", ""2885"", ""6662""]}}]",CRITICAL,"List of protein-coding genes on chromosome 17 including BRCA1, TP53, ERBB2, and others","COMPLEX QUERY requiring Ensembl structure knowledge.

Databases/Resources: Ensembl

Knowledge Required:
- Species filter: obo:RO_0002162 taxonomy:9606 (CRITICAL for human)
- Chromosome filter: CONTAINS(STR(?chr), 'GRCh38/17')
- Biotype filter for protein-coding: ENSGLOSSARY_0000026
- Without species filter: Results mix multiple species

Without proper knowledge: Query returns results from mouse, pig, zebrafish, etc.

Verified in ensembl_exploration.md Pattern 1 (Species Filtering)."
27,2026-02-01,Integration,What UniProt protein IDs are targeted by the cancer drug Sorafenib?,True,True,True,0.5,"Sorafenib is a multi-kinase inhibitor used primarily for treating renal cell carcinoma and hepatocellular carcinoma. Based on my training knowledge, Sorafenib targets several protein kinases with the following UniProt IDs:

**Primary targets:**
- **P07949** - RAF1 (Raf-1 proto-oncogene serine/threonine kinase)
- **P15056** - BRAF (B-Raf proto-oncogene serine/threonine kinase)
- **P35968** - KDR/VEGFR2 (Vascular endothelial growth factor receptor 2)
- **P17948** - FLT1/VEGFR1 (Vascular endothelial growth factor receptor 1)
- **P36888** - FLT3 (FMS-like tyrosine kinase 3)
- **Q02763** - FLT4/VEGFR3 (Vascular endothelial growth factor receptor 3)
- **P10721** - KIT (Mast/stem cell growth factor receptor Kit)
- **P16234** - PDGFRA (Platelet-derived growth factor receptor alpha)
- **P09619** - PDGFRB (Platelet-derived growth factor receptor beta)
- **P07332** - FES (Feline sarcoma proto-oncogene tyrosine kinase)

**Additional targets:**
- **P04049** - RAF1 (alternative entry, same as P07949)
- **P01133** - EGF (indirectly through receptor inhibition)

The primary mechanism of action involves inhibiting the RAF/MEK/ERK signaling pathway and angiogenesis through VEGFR inhibition.

Please note that binding affinity and clinical relevance vary among these targets.",,10.220930814743042,56,445,True,True,0.625,"Excellent! Now let me filter for the key targets that Sorafenib is known to target specifically. Let me search for information about Sorafenib's primary targets to provide you with the most relevant ones:

Based on the ChEMBL database query, **Sorafenib (CHEMBL1336) targets numerous proteins**. The compound has been tested against hundreds of kinases and receptors. Here are the **primary therapeutic targets** of Sorafenib with their UniProt IDs:

## Key Primary Targets (RAF kinases and VEGFRs):

1. **Serine/threonine-protein kinase B-raf** - **P15056** (Human BRAF)
2. **Serine/threonine-protein kinase RAF** - **P04049** (Human CRAF/RAF1)
3. **Vascular endothelial growth factor receptor 2** - **P35968** (Human VEGFR2/KDR)
4. **Vascular endothelial growth factor receptor 3** - **P35916** (Human VEGFR3/FLT4)
5. **Vascular endothelial growth factor receptor 1** - **P17948** (Human VEGFR1/FLT1)

## Other Important Kinase Targets:

6. **Platelet-derived growth factor receptor beta** - **P09619** (Human PDGFRβ)
7. **Platelet-derived growth factor receptor alpha** - **P16234** (Human PDGFRα)
8. **Stem cell growth factor receptor** - **P10721** (Human c-KIT)
9. **Tyrosine-protein kinase receptor FLT3** - **P36888** (Human FLT3)
10. **Tyrosine-protein kinase receptor RET** - **P07949** (Human RET)

Sorafenib is a **multi-kinase inhibitor** approved for treating hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. It primarily works by inhibiting RAF kinases (involved in cell proliferation) and VEGF receptors (involved in angiogenesis), thereby blocking both tumor cell proliferation and tumor blood vessel formation.",,84.76942896842957,51,3977,25470,409848,"mcp__togomcp__search_chembl_molecule, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__get_pubchem_compound_id, mcp__togomcp__get_compound_attributes_from_pubchem, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""Sorafenib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?targetName ?uniprotId\nWHERE {\n  ?molecule a chembl:SmallMolecule ;\n            chembl:chemblId \""CHEMBL1336\"" ;\n            chembl:hasActivity ?activity .\n  \n  ?activity chembl:hasAssay ?assay .\n  \n  ?assay chembl:hasTarget ?target .\n  \n  ?target a chembl:SingleProtein ;\n          chembl:hasTargetComponent ?component ;\n          chembl:preferredName ?targetName .\n  \n  ?component cco:targetCmptXref ?xref .\n  \n  ?xref a cco:UniprotRef ;\n        chembl:xrefId ?uniprotId .\n}\nORDER BY ?targetName""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?targetName ?uniprotAcc\nWHERE {\n  ?molecule chembl:chemblId \""CHEMBL1336\"" .\n  ?activity chembl:hasMolecule ?molecule .\n  ?assay chembl:hasActivity ?activity .\n  ?assay chembl:hasTarget ?target .\n  ?target chembl:preferredName ?targetName .\n  \n  OPTIONAL {\n    ?target chembl:hasTargetComponent ?component .\n    ?component chembl:targetCmptXref ?xref .\n    ?xref chembl:xrefSrc \""UniProt\"" ;\n          chembl:xrefId ?uniprotAcc .\n  }\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?target ?targetLabel ?component ?uniprotId\nWHERE {\n  ?molecule chembl:chemblId \""CHEMBL1336\"" .\n  ?activity chembl:hasMolecule ?molecule .\n  ?assay chembl:hasActivity ?activity .\n  ?assay chembl:hasTarget ?target .\n  ?target rdfs:label ?targetLabel .\n  \n  ?target chembl:hasTargetComponent ?component .\n  ?component chembl:targetCmptXref ?xref .\n  ?xref chembl:xrefId ?uniprotId .\n  FILTER(CONTAINS(STR(?xref), \""uniprot\""))\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__get_pubchem_compound_id"", ""input"": {""compound_name"": ""sorafenib""}}, {""name"": ""mcp__togomcp__get_compound_attributes_from_pubchem"", ""input"": {""pubchem_compound_id"": ""216239""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?uniprotAcc ?proteinName\nWHERE {\n  VALUES ?chemblId { \""CHEMBL1336\"" }\n  \n  ?molecule cco:chemblId ?chemblId .\n  ?activity cco:hasMolecule ?molecule .\n  ?assay cco:hasActivity ?activity .\n  ?assay cco:hasTarget ?target .\n  \n  ?target cco:hasTargetComponent ?component .\n  ?component cco:targetCmptXref ?xref .\n  ?xref cco:xrefSrc \""UniProt\"" .\n  ?xref cco:xrefId ?uniprotAcc .\n  \n  OPTIONAL { ?target cco:preferredName ?proteinName }\n}\nORDER BY ?uniprotAcc""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT DISTINCT ?activity ?target\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1336> chembl:hasActivity ?activity .\n  ?activity rdf:type chembl:Activity .\n  ?activity chembl:hasAssay ?assay .\n  ?assay chembl:hasTarget ?target .\n}\nLIMIT 20""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?targetId ?targetName ?uniprotId\nWHERE {\n  VALUES ?target {\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL2695>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL2918>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL4246>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL4225>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL1862>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL3956>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL3920>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL3788>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL2426>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL394>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL1906>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL4442>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL364>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL2041>\n  }\n  \n  ?target chembl:chemblId ?targetId .\n  OPTIONAL { ?target chembl:preferredName ?targetName }\n  \n  ?target chembl:hasTargetComponent ?component .\n  ?component chembl:targetCmptXref ?xref .\n  ?xref chembl:xrefSrc \""UniProt\"" ;\n        chembl:xrefId ?uniprotId .\n}\nORDER BY ?targetName""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?targetLabel ?component ?xref ?xrefId\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL2695> rdfs:label ?targetLabel .\n  <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL2695> chembl:hasTargetComponent ?component .\n  ?component chembl:targetCmptXref ?xref .\n  ?xref chembl:xrefId ?xrefId .\n}\nLIMIT 10""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT ?p ?o\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL2695> ?p ?o .\n}\nLIMIT 30""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT ?component ?p ?o\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL2695> chembl:hasTargetComponent ?component .\n  ?component ?p ?o .\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?targetLabel ?uniprotId\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1336> chembl:hasActivity ?activity .\n  ?activity chembl:hasAssay ?assay .\n  ?assay chembl:hasTarget ?target .\n  ?target a chembl:SingleProtein .\n  ?target rdfs:label ?targetLabel .\n  ?target chembl:hasTargetComponent ?component .\n  ?component chembl:targetCmptXref ?xref .\n  FILTER(CONTAINS(STR(?xref), \""uniprot.org/uniprot\""))\n  BIND(STRAFTER(STR(?xref), \""uniprot.org/uniprot/\"") AS ?uniprotId)\n}\nORDER BY ?targetLabel""}}]",VALUABLE,List of UniProt IDs for Sorafenib targets including various kinases and receptors,"COMPLEX QUERY requiring ChEMBL-UniProt integration knowledge.

Databases/Resources: ChEMBL

Knowledge Required:
- Target → TargetComponent → skos:exactMatch path
- STRSTARTS filter for UniProt URI pattern
- Drug lookup by name then target traversal

Without proper knowledge: Cannot navigate Target-TargetComponent-UniProt relationship.

Verified in chembl_exploration.md Pattern 8 (Target-UniProt Mapping)."
28,2026-02-01,Integration,What genes are mentioned together with diabetes in PubMed literature?,True,False,True,0.6,"I don't have access to real-time PubMed databases or the ability to search current literature. However, I can tell you about genes that are commonly mentioned together with diabetes in the scientific literature based on my training knowledge:

## Type 1 Diabetes-Associated Genes:
- **HLA genes** (HLA-DQ, HLA-DR) - strongest genetic risk factors
- **INS** (insulin gene)
- **PTPN22** (protein tyrosine phosphatase)
- **CTLA4** (cytotoxic T-lymphocyte antigen 4)
- **IL2RA** (interleukin-2 receptor alpha)

## Type 2 Diabetes-Associated Genes:
- **TCF7L2** - one of the strongest genetic risk factors
- **PPARG** (peroxisome proliferator-activated receptor gamma)
- **KCNJ11** (potassium channel gene)
- **IRS1/IRS2** (insulin receptor substrate genes)
- **FTO** (fat mass and obesity-associated gene)
- **SLC30A8** (zinc transporter)
- **CDKN2A/CDKN2B**
- **IGF2BP2**
- **HHEX**

## Monogenic Diabetes Genes:
- **GCK** (glucokinase) - MODY2
- **HNF1A, HNF4A, HNF1B** - various MODY types
- **ABCC8, KCNJ11** - neonatal diabetes

For current, comprehensive co-mention analysis from PubMed, you would need to use literature mining tools or PubMed's own search features.",,8.587443113327026,51,412,True,True,0.6,"Based on the search results from PubMed, I found numerous genes that are mentioned together with diabetes in the literature. Let me analyze the abstracts to identify the specific genes discussed:

## Key Genes Mentioned with Diabetes in Recent PubMed Literature:

### **Diabetes-Associated Genes from Retrieved Articles:**

1. **MEG3 (Maternally Expressed Gene 3)** - A tumor suppressor and T1D risk gene highly expressed in beta cells, involved in cytokine-induced damage and apoptosis

2. **MyD88 (Myeloid Differentiation Primary Response Gene 88)** - Plays a critical role in inflammation-driven diabetic complications

3. **WFS1 (Wolfram Syndrome 1)** - Associated with early-onset diabetes and Wolfram syndrome

4. **GLP1R (Glucagon-like Peptide-1 Receptor)** - Central to diabetes treatment with GLP-1 receptor agonists

5. **TCF7L2 (Transcription Factor 7-Like 2)** - Well-known type 2 diabetes susceptibility gene

6. **PPAR-γ (Peroxisome Proliferator-Activated Receptor Gamma)** - Involved in glucose homeostasis and insulin sensitivity

7. **ABCC8 and KCNJ11** - Genes encoding ATP-sensitive potassium channels involved in neonatal diabetes mellitus

8. **GLIS3, PAX6, GATA6** - Transcription factors that impair pancreatic development

9. **HNF1A** - Associated with monogenic diabetes

10. **FTO, ADAMTSL3, CYP4F2, DPP8** - Genes identified in polygenic risk scores for metabolic complications

11. **IL5RA (Interleukin-5 Receptor Alpha)** - Showed strong genetic association with lower limb skeletal muscle mass

12. **HSPA12B (Heat Shock Protein A12B)** - Involved in cold adaptation and glucose metabolism

13. **APP, SERPINA3C, MAP2, ADAM9, LRP8, CASP3, ABCA1** - Genes altered in Alzheimer's disease models treated with diabetes medications

### **Gene Pathways and Networks:**

According to PubMed, several key pathways are consistently mentioned:
- **Insulin secretion pathways**
- **Inflammatory signaling** (TLR4-MyD88, MAPK, NF-κB)
- **Beta-cell development and function**
- **Glucose metabolism**
- **Oxidative phosphorylation**

These findings represent the diverse genetic landscape of diabetes, spanning from monogenic forms (like neonatal diabetes) to polygenic type 2 diabetes, and including genes involved in complications such as diabetic nephropathy and neuropathy.

**Sources:**
- [DOI: 10.1038/s41418-026-01669-x](https://doi.org/10.1038/s41418-026-01669-x)
- [DOI: 10.1016/j.ejphar.2026.178603](https://doi.org/10.1016/j.ejphar.2026.178603)
- [DOI: 10.3390/cimb48010104](https://doi.org/10.3390/cimb48010104)
- [DOI: 10.3390/cimb47121053](https://doi.org/10.3390/cimb47121053)
- [DOI: 10.1093/jas/skag016](https://doi.org/10.1093/jas/skag016)",,35.7645320892334,12,1149,25503,79052,"mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""diabetes AND gene[Title/Abstract]"", ""max_results"": 50}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41617975"", ""41617168"", ""41616952"", ""41616609"", ""41615759"", ""41615431"", ""41614934"", ""41614817"", ""41614771"", ""41614693"", ""41613956"", ""41613876"", ""41613784"", ""41613128"", ""41613116"", ""41612851"", ""41612266"", ""41612102"", ""41611467"", ""41611293""]}}]",CRITICAL,"Genes frequently co-mentioned with diabetes in PubMed such as INS, PPARG, TCF7L2, and others","COMPLEX QUERY requiring PubTator text mining knowledge.

Databases/Resources: PubTator, PubMed

Knowledge Required:
- dcterms:subject 'Disease' and 'Gene' annotation types
- oa:hasBody for entity IDs (MeSH, NCBI Gene)
- oa:hasTarget for article linkage
- bif:contains pre-filtering BEFORE cross-database join
- Co-occurrence analysis via shared articles

Without proper knowledge: Query times out from 37M × 10M Cartesian product.

Verified in pubtator_exploration.md Pattern 1 (Gene-Disease Co-occurrence)."
29,2026-02-01,Completeness,How many biochemical reactions involve NADH as a substrate or product?,True,False,True,0.6666666666666666,"I don't have access to a specific number for how many biochemical reactions involve NADH as a substrate or product with certainty.

However, I can tell you that NADH is involved in a **very large number** of biochemical reactions - likely in the hundreds to thousands range across all known metabolic pathways. This is because:

1. **Central metabolism**: NADH is a key cofactor in glycolysis, the citric acid cycle (Krebs cycle), and oxidative phosphorylation

2. **Biosynthetic pathways**: Many reductive biosynthetic reactions use NADH or NADPH

3. **Catabolic pathways**: Breakdown of amino acids, fatty acids, and other biomolecules often produces NADH

4. **Fermentation pathways**: Various fermentation reactions interconvert NAD+ and NADH

5. **Detoxification reactions**: Many oxidoreductases use NADH

The exact number would depend on:
- Which organism(s) you're considering
- Whether you count similar reactions in different species separately
- Whether you include both NADH and its phosphorylated form NADPH
- Which metabolic databases you reference (like KEGG, MetaCyc, or Reactome)

If you need a specific number, I'd recommend consulting biochemical databases like KEGG or MetaCyc, which catalog these reactions systematically.",,7.60460901260376,52,317,True,True,1.0,"Based on my search of the Rhea biochemical reactions database, I found **over 1,000 reactions involving NADH** as either a substrate or product. The exact count is difficult to determine from the truncated output, but the search returned hundreds of distinct Rhea reaction IDs.

These NADH-involving reactions span a wide variety of biochemical processes, including:

1. **Oxidation-reduction reactions** - NADH serves as a reducing agent or is produced during oxidation
2. **Metabolic pathways** - Including glycolysis, TCA cycle, fatty acid metabolism, amino acid metabolism
3. **Respiratory chain reactions** - Where NADH transfers electrons to quinones (ubiquinone, menaquinone)
4. **Biosynthetic reactions** - Production of various metabolites, steroids, bile acids
5. **Xenobiotic degradation** - Breaking down aromatic compounds, pollutants
6. **Hydroxylation reactions** - Adding hydroxyl groups to various substrates

Some major categories include:
- **Dehydrogenases** - Converting alcohols to ketones/aldehydes and vice versa
- **Reductases** - Reducing double bonds, quinones, or other oxidized species
- **Oxidases** - Coupled with oxygen to oxidize substrates
- **Energy transduction** - Proton pumping coupled to NADH oxidation

NADH is one of the most important cofactors in biochemistry, serving as a universal electron carrier in cellular metabolism. The true number across all organisms and biological systems is likely in the **thousands of reactions**.",,20.239556789398193,8,477,51021,52263,mcp__togomcp__search_rhea_entity,"[{""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""NADH"", ""limit"": 10000}}]",CRITICAL,"1,101 reactions involving NADH","COMPLEX QUERY requiring compound-reaction knowledge.

Databases/Resources: Rhea

Knowledge Required:
- ChEBI compound linkage via rdfs:subClassOf
- NADH ChEBI ID: CHEBI:57945
- Reaction-side-participant-compound traversal path
- rhea:status rhea:Approved filter

Without proper knowledge: Cannot identify compound-reaction relationships through correct path.

Verified in rhea_exploration.md Pattern 3."
30,2026-02-01,Completeness,How many bacterial strains are recorded in the BacDive database?,True,False,True,0.8,"I don't have access to real-time information about the current number of bacterial strains in the BacDive database. BacDive (the Bacterial Diversity Metadatabase) is actively maintained and regularly updated by the Leibniz Institute DSMZ, so the number of strains changes over time as new data is added.

As of my last training data, BacDive contained information on tens of thousands of bacterial and archaeal strains, but I cannot provide you with the exact current number with certainty. For the most accurate and up-to-date count, I recommend visiting the official BacDive website (bacdive.dsmz.de) directly, where they typically display current statistics about their database coverage.",,4.958953857421875,52,163,True,True,0.8,"Perfect! I now have the exact count. Based on the SPARQL query results from the BacDive RDF database, **BacDive contains 97,334 bacterial strain records**.

This aligns closely with the database description which mentioned ""97,000+ strain records."" BacDive (Bacterial Diversity Metadatabase) provides standardized information about bacterial and archaeal strains, covering aspects like:

- Taxonomy
- Morphology
- Physiology
- Cultivation conditions
- Molecular data (including 87,045 nucleotide sequences)
- Phenotypic and genotypic characterizations

The database also includes extensive related data such as 573,112 enzyme/protein entries, 155,056 culture condition records, and 149,377 culture collection numbers that provide comprehensive information about these strains.",,54.48898196220398,42,1110,16968,249855,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__list_databases, mcp__togomcp__run_sparql, mcp__togomcp__get_graph_list, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""bacdive"", ""sparql_query"": ""\nSELECT (COUNT(DISTINCT ?strain) AS ?strainCount)\nWHERE {\n  ?strain a <http://bacdive.dsmz.de/ontology#Strain> .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""bacdive"", ""sparql_query"": ""\nSELECT (COUNT(*) AS ?total)\nWHERE {\n  ?s ?p ?o .\n}\nLIMIT 1\n""}}, {""name"": ""mcp__togomcp__list_databases"", ""input"": {}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""bacdive"", ""sparql_query"": ""\nPREFIX bd: <http://bacdive.dsmz.de/>\nSELECT (COUNT(DISTINCT ?strain) AS ?count)\nWHERE {\n  ?strain a bd:Strain .\n}\n""}}, {""name"": ""mcp__togomcp__get_graph_list"", ""input"": {""dbname"": ""bacdive""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""bacdive"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT (COUNT(DISTINCT ?s) AS ?count)\nFROM <http://rdfportal.org/dataset/bacdive>\nWHERE {\n  ?s rdf:type ?type .\n  FILTER(CONTAINS(STR(?type), \""Strain\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""bacdive"", ""sparql_query"": ""\nSELECT DISTINCT ?type (COUNT(?s) AS ?count)\nFROM <http://rdfportal.org/dataset/bacdive>\nWHERE {\n  ?s a ?type .\n}\nGROUP BY ?type\nORDER BY DESC(?count)\nLIMIT 20\n""}}]",CRITICAL,"97,334 bacterial and archaeal strains (95,742 Bacteria + 1,049 Archaea)","COMPLEX QUERY requiring BacDive structure knowledge.

Databases/Resources: BacDive

Knowledge Required:
- Hub-and-spoke data model with Strain as central entity
- GRAPH clause: <http://rdfportal.org/dataset/bacdive>
- Domain filtering for Bacteria vs Archaea
- describesStrain relationship pattern

Without proper knowledge: Cannot navigate hub-and-spoke data model.

Verified in bacdive_exploration.md Dataset Statistics."
31,2026-02-01,Specificity,What are the most well-studied pathogenic variants in ClinVar with strong evidence from multiple laboratories?,True,True,False,0.46153846153846156,"Based on my training knowledge, some of the most well-studied pathogenic variants in ClinVar with strong evidence from multiple laboratories include:

## Classic High-Penetrance Cancer Variants

**BRCA1 and BRCA2:**
- BRCA1 c.68_69delAG (185delAG) - founder mutation in Ashkenazi Jewish population
- BRCA1 c.5266dupC (5382insC) - another Ashkenazi founder mutation
- BRCA2 c.5946delT (6174delT) - Ashkenazi founder mutation
- These have been studied by dozens of laboratories with thousands of families

## Common Disease-Causing Variants

**CFTR (Cystic Fibrosis):**
- c.1521_1523delCTT (p.Phe508del/F508del) - most common CF mutation (~70% of CF chromosomes)
- Extensively validated across hundreds of laboratories worldwide

**HFE (Hereditary Hemochromatosis):**
- c.845G>A (p.Cys282Tyr/C282Y) - most common causative variant
- c.187C>G (p.His63Asp/H63D) - risk modifier
- Very well characterized in European populations

## Cardiovascular Disease

**LDLR (Familial Hypercholesterolemia):**
- Multiple recurrent variants with extensive clinical validation
- Often have 10+ submitters in ClinVar

**MYBPC3, MYH7 (Hypertrophic Cardiomyopathy):**
- Several founder mutations with large family studies

## Neurological Conditions

**Factor V Leiden:**
- F5 c.1601G>A (p.Arg534Gln) - thrombophilia risk
- One of the most commonly tested variants

These variants typically have:
- 3+ stars in ClinVar (expert panel reviewed or multiple submitters with consensus)
- Published functional studies
- Large patient cohorts
- Population frequency data across multiple databases

The actual number of submitters and evidence level can be verified directly in ClinVar's database.",,12.60250210762024,58,506,True,False,0.23076923076923078,"Based on my search of ClinVar, I can provide you with information about well-studied pathogenic variants, though the database structure makes it challenging to directly query by number of submitters. Here's what I found:

## Most Well-Studied Pathogenic Variants in ClinVar

The most extensively studied pathogenic variants tend to be in **cancer predisposition genes**, particularly:

### **BRCA1 and BRCA2 (Breast/Ovarian Cancer)**
- **BRCA1**: 13,961 pathogenic/likely pathogenic variants
- **BRCA2**: 18,208 pathogenic/likely pathogenic variants

These are among the most comprehensively studied genes in ClinVar due to their clinical importance in hereditary breast and ovarian cancer syndrome.

**Example well-documented BRCA variants:**
- **BRCA2 c.9477_9478insTTGAC** (p.Asn3160fs) - frameshift variant, likely pathogenic
- **BRCA2 c.4621A>T** (p.Lys1541Ter) - nonsense variant, likely pathogenic
- **BRCA1 c.4228G>A** (p.Glu1410Lys) - missense variant

### **TP53 (Li-Fraumeni Syndrome)**
- **1,704 pathogenic/likely pathogenic variants**
- Critical tumor suppressor gene with extensive clinical evidence

### **Other Highly Studied Genes:**
- **ATM**: DNA repair gene associated with familial breast cancer
- **LDLR**: Familial hypercholesterolemia - well-characterized with multiple pathogenic variants
- **APOB**: Also associated with familial hypercholesterolemia

## Key Characteristics of Well-Studied Variants:

1. **Clinical Validity**: Variants with practice guideline support or reviewed by expert panels
2. **Multiple Submissions**: Variants reported by multiple clinical laboratories independently
3. **Functional Evidence**: Strong biological evidence (nonsense, frameshift, canonical splice site variants)
4. **Population Studies**: Variants with consistent pathogenic classifications across large patient cohorts

The variants in BRCA1/BRCA2 and TP53 represent some of the most robust evidence in ClinVar, as these genes have been subject to extensive clinical genetic testing, functional studies, and expert review panels over decades of research.",,49.975096225738525,28,1535,15201,185903,"mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch","[{""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""pathogenic[Clinical significance] AND reviewed by expert panel[Review status]"", ""max_results"": 20, ""sort_by"": ""relevance""}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""pathogenic AND practice guideline"", ""max_results"": 20}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""pathogenic AND criteria provided multiple submitters"", ""max_results"": 20}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""clinvar"", ""ids"": [""4686632"", ""4686574"", ""4686571"", ""4686569"", ""4686568"", ""4686567"", ""4686566"", ""4686565"", ""4683179"", ""4683176""]}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""pathogenic[Clinical significance] AND multiple submitters[Review status]"", ""max_results"": 30}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1[gene] AND pathogenic[Clinical significance]"", ""max_results"": 20}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA2[gene] AND pathogenic[Clinical significance]"", ""max_results"": 20}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""TP53[gene] AND pathogenic[Clinical significance]"", ""max_results"": 20}}]",VALUABLE,"High-confidence pathogenic variants such as GJB2 c.35del (80 submitters), BRCA1 c.68_69del (78 submitters), CFTR p.Phe508del (78 submitters)","COMPLEX QUERY requiring classification and evidence filtering.

Databases/Resources: ClinVar

Knowledge Required:
- Property path for clinical significance classification
- number_of_submitters for evidence strength
- Combined filtering on multiple criteria
- record_status 'current' filter

Without proper knowledge: Unable to navigate nested classification structure or combine filters effectively.

Verified in clinvar_exploration.md Pattern 3 (Clinical Significance Filtering)."
32,2026-02-01,Specificity,What culture media are available for growing thermophilic bacteria?,True,True,True,0.5555555555555556,"Several culture media are suitable for growing thermophilic bacteria, ranging from general-purpose to specialized formulations:

## General Purpose Media

1. **Tryptic Soy Agar/Broth (TSA/TSB)** - widely used, nutrient-rich medium that supports many thermophiles

2. **Nutrient Agar/Broth** - basic medium suitable for non-fastidious thermophiles

3. **Luria-Bertani (LB) medium** - commonly used for bacterial thermophiles

## Specialized Media for Specific Thermophiles

4. **Thermus Medium (TM)** - designed for *Thermus* species (e.g., *T. aquaticus*)
   - Contains peptone, yeast extract, and mineral salts

5. **Bacillus Medium** - for thermophilic *Bacillus* and *Geobacillus* species

6. **DSM Medium 88** - for various thermophilic bacteria

## For Extreme Thermophiles/Hyperthermophiles

7. **Marine Broth 2216** - for marine thermophiles

8. **Modified SME Medium** - for sulfur-metabolizing thermophiles

9. **Pyrobaculum Medium** - for archaeal thermophiles

## Minimal/Defined Media

10. **Mineral Salts Medium** - with specific carbon sources for autotrophic or specialized thermophiles

## Key Considerations

- **Incubation temperature**: typically 50-80°C for thermophiles, up to 100°C+ for hyperthermophiles
- **pH adjustment**: some thermophiles require acidic or alkaline conditions
- **Anaerobic conditions**: may be needed for certain species
- **Sulfur supplementation**: important for some extreme thermophiles

The choice depends on the specific organism and its nutritional requirements.",,9.744403839111328,50,442,True,True,0.5555555555555556,"Based on articles retrieved from PubMed, here are several culture media options available for growing thermophilic bacteria:

## General Media Types

**1. Nutrient-Rich Complex Media**
- According to research on thermophilic bacteria, complex media are commonly used and include:
  - **Yeast extract** - a standard nutrient source
  - **Peptone** - provides amino acids and peptides
  - **N-acetyl-glucosamine** - a preferred carbon/nitrogen source
  - **Oligoelements and macroelements** - essential minerals

**2. Defined Minimal Media**
- Minimal media can be used but may require supplementation with growth factors
- Some thermophiles show auxotrophic requirements and need additional nutrients

**3. Specialized Media for Specific Thermophiles**

According to research on *Clostridium thermocellum* and related species ([DOI](https://doi.org/10.1007/s00449-020-02490-7)):
- **Defined minimal medium** supplemented with wheat straw extractives
- These extractives provide essential growth factors that support auxotrophic strains
- The medium supports lignocellulosic degradation

For thermophilic Streptomyces species ([DOI](https://doi.org/10.30498/ijb.2021.272122.2979)):
- **Cheap culture media** optimized for thermostable enzyme production
- Media designed for optimal growth at elevated temperatures

**4. Oligotrophic Media**
According to a comprehensive review ([DOI](https://doi.org/10.3389/fcimb.2020.519301)), many thermophiles grow in:
- **Nutrient-poor oligotrophic environments**
- **Biphasic media** - combining host-associated extracts with diluted basal medium
- Media with pH range from 3.4 to 11 (depending on species)

**5. Temperature-Specific Media for Extreme Thermophiles**
Research on acidophilic thermophiles shows they can grow in:
- Standard acidophile media at temperatures of **50-60°C**
- Media tolerating high concentrations of rare earth elements (for certain applications)

## Key Considerations:

1. **Temperature range**: Most thermophiles are mesophilic to moderately thermophilic (50-60°C)
2. **pH requirements**: Can vary widely from acidic (pH 3.4) to alkaline (pH 11)
3. **Nutrient concentration**: Many prefer oligotrophic (low-nutrient) conditions
4. **Growth factors**: Cross-feeding between species or environmental extracts may be necessary
5. **Seasonality**: Some thermophiles show better growth during specific seasons

The choice of medium depends on your specific thermophilic species and application. For isolation of new strains, mimicking natural environmental conditions with appropriate extracts and diluted media often yields the best results.",,35.15812373161316,22,1031,6856,105724,"mcp__bacdive__search, mcp__togomcp__search_mesh_descriptor, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__bacdive__search"", ""input"": {""query"": ""thermophilic culture media""}}, {""name"": ""mcp__togomcp__search_mesh_descriptor"", ""input"": {""query"": ""thermophilic bacteria culture media"", ""limit"": 10}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""thermophilic bacteria culture media growth"", ""max_results"": 10}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""40987947"", ""38135188"", ""35891952"", ""33392746"", ""33330115""]}}]",VALUABLE,Culture media for thermophiles including high-temperature media from MediaDive database,"COMPLEX QUERY requiring MediaDive structure knowledge.

Databases/Resources: MediaDive, BacDive

Knowledge Required:
- Cross-database integration via BacDiveID
- Temperature filtering in BacDive (CultureTemperature > 60°C)
- Pre-filtering by phenotype BEFORE MediaDive join
- GRAPH clauses for both databases on primary endpoint

Without proper knowledge: Query times out without pre-filtering (97K strains × 3K media).

Verified in mediadive_exploration.md Pattern 2 (Pre-filtering Before Joins)."
33,2026-02-01,Currency,What protein structures were determined using cryo-electron microscopy?,True,True,True,0.8,"I can provide some notable examples of protein structures determined using cryo-electron microscopy (cryo-EM), though this is not an exhaustive list as thousands of structures have been solved with this technique:

## Historic/Landmark Structures:
- **Ribosome** - One of the early major achievements, with structures from various organisms
- **Spliceosome** - Multiple states of this RNA-protein complex
- **Proteasome** - The cellular protein degradation machinery

## Viral Structures:
- **Zika virus**
- **HIV envelope proteins**
- **SARS-CoV-2 spike protein** - Critical for COVID-19 research
- Various other viral capsids and envelope proteins

## Membrane Proteins:
- **TRPV1 ion channel**
- **Voltage-gated sodium channels**
- **GABA receptors**
- **Glutamate receptors**
- **ABC transporters**

## Large Protein Complexes:
- **Nuclear pore complex components**
- **RNA polymerases** (various types)
- **Hemoglobin** (historically, though now mainly X-ray)
- **Gamma-secretase**
- **Tau filaments** (Alzheimer's disease-related)

## Recent Notable Examples:
- **AlphaFold-predicted structures** verified by cryo-EM
- Various **CRISPR-Cas complexes**
- **Telomerase**

Cryo-EM has been particularly revolutionary for large complexes, membrane proteins, and flexible assemblies that are difficult to crystallize for X-ray crystallography. The technique earned the 2017 Nobel Prize in Chemistry.",,9.231032848358154,50,391,True,True,0.8,"Great! I found a large collection of protein structures determined using cryo-electron microscopy. The search returned **11,158 total structures** in the PDB that were determined using cryo-EM.

Here are some notable examples from the results:

## Representative Cryo-EM Structures:

1. **Ribosomal structures:**
   - PDB 4A2I: 30S ribosomal subunit with YjeQ biogenesis factor
   - PDB 4V8M: High-resolution *Trypanosoma brucei* ribosome

2. **Ion channels:**
   - PDB 5W3S: TRPML3 ion channel
   - PDB 5TR1/5TQQ: Bovine CLC-K chloride channels
   - PDB 5AN8: Rabbit TRPV2 ion channel

3. **Viral proteins:**
   - PDB 6B7N: Porcine delta coronavirus spike protein
   - PDB 3JCL: Coronavirus spike glycoprotein trimer
   - PDB 3CNF: Cytoplasmic polyhedrosis virus (3.88 Å)
   - PDB 4D1K: HIV-1 Gag tubular arrays

4. **Enzymes:**
   - PDB 3J7H: β-galactosidase at 3.2 Å resolution
   - PDB 8YT4: Lumazine synthase at **1.42 Å resolution** (remarkably high!)
   - PDB 9GRE/9GRD: Glucose/xylose isomerase
   - PDB 8D44: Human fructose-bisphosphate aldolase B

5. **Other complexes:**
   - PDB 6BDF: 20S proteasome at 2.8 Å resolution
   - PDB 6N38: Type VI secretion system baseplate

The structures span a wide range of resolutions and biological systems, showcasing cryo-EM's versatility in determining structures of large complexes, membrane proteins, and viral assemblies that were historically challenging for X-ray crystallography.",,21.183993101119995,9,652,1250,52261,mcp__togomcp__search_pdb_entity,"[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""cryo-electron microscopy"", ""limit"": 20}}]",VALUABLE,"15,032 structures determined by electron microscopy, including ribosomes, membrane proteins, and viral structures","COMPLEX QUERY requiring experimental method knowledge.

Databases/Resources: PDB

Knowledge Required:
- exptl.method property for experimental technique
- Value: 'ELECTRON MICROSCOPY'
- FROM graph clause for optimization
- COUNT pattern for completeness

Without proper knowledge: Cannot correctly filter by experimental method.

Verified in pdb_exploration.md Pattern 4 (Experimental Method Distribution)."
34,2026-02-01,Currency,What antimicrobial resistance patterns are most prevalent in Salmonella isolates?,True,True,True,0.75,"# Prevalent Antimicrobial Resistance Patterns in Salmonella

Based on current surveillance data, here are the most common resistance patterns observed in Salmonella isolates:

## Most Common Resistance Patterns

### 1. **ACSSuT Pattern (Pentaresistance)**
- **Antibiotics**: Ampicillin, Chloramphenicol, Streptomycin, Sulfonamides, Tetracycline
- Historically very common in S. Typhimurium DT104
- Still prevalent in certain serovars and regions

### 2. **Extended-Spectrum β-Lactamase (ESBL) Resistance**
- Resistance to 3rd-generation cephalosporins (ceftriaxone, cefotaxime)
- Often mediated by CTX-M, SHV, or TEM enzymes
- Increasingly reported in S. Kentucky, S. Infantis, and other serovars

### 3. **Fluoroquinolone Resistance**
- Reduced susceptibility to ciprofloxacin and other fluoroquinolones
- Common mechanisms: chromosomal mutations (gyrA, parC) and plasmid-mediated quinolone resistance (PMQR)
- Particularly prevalent in S. Kentucky and Asian/Middle Eastern isolates

### 4. **MDR (Multi-Drug Resistance)**
- Resistance to ≥3 antimicrobial classes
- Common combinations include:
  - Ampicillin + streptomycin + sulfonamides + tetracycline
  - Adding trimethoprim-sulfamethoxazole or chloramphenicol

## Serovar-Specific Patterns

- **S. Typhimurium**: ACSSuT, increasing fluoroquinolone resistance
- **S. Kentucky**: High rates of fluoroquinolone and ESBL resistance
- **S. Infantis**: Emerging ESBL producer
- **S. Newport**: MDR patterns including cephalosporin resistance

## Concerning Trends

- **Colistin resistance** (mcr genes): Emerging concern
- **Carbapenem resistance**: Rare but increasingly reported
- **Pan-resistant strains**: Occasional reports, particularly in immunocompromised patients

Geographic and temporal variations exist, so local surveillance data should guide treatment decisions.",,10.863409757614136,55,555,True,True,0.8333333333333334,"Based on the research articles retrieved from PubMed, here are the most prevalent antimicrobial resistance patterns in Salmonella isolates:

## Most Common Antimicrobial Resistance Patterns

### **Multidrug Resistance (MDR)**
According to PubMed, multidrug resistance is extremely prevalent across Salmonella isolates:
- **68.7% MDR rate** observed in retail meats in Hong Kong ([DOI](https://doi.org/10.1016/j.foodres.2025.117918))
- **93% third-generation cephalosporin resistance** and **93% MDR** reported in recent years ([DOI](https://doi.org/10.1016/j.foodres.2025.117918))

### **Specific Resistance Patterns by Antibiotic Class**

**1. Fluoroquinolones**
- **69.6% ciprofloxacin resistance** in Hong Kong retail meat samples ([DOI](https://doi.org/10.1016/j.foodres.2025.117918))
- Nalidixic acid resistance is widespread, often associated with gyrA mutations (D87Y) ([DOI](https://doi.org/10.1016/j.jiph.2025.103053))

**2. Beta-lactams**
- Resistance to **ampicillin** and **cephalosporins** (including 3rd generation like ceftriaxone)
- **7.8% ceftriaxone resistance** ([DOI](https://doi.org/10.1016/j.foodres.2025.117918))

**3. Macrolides**
- **8.3% azithromycin resistance** reported ([DOI](https://doi.org/10.1016/j.foodres.2025.117918))

**4. Other Classes**
- **Tetracycline resistance** - very common
- **Chloramphenicol resistance**
- **Sulfonamide resistance** (sul genes)
- **Trimethoprim resistance** (dfrA genes)
- **Aminoglycoside resistance** (aadA genes)

### **Most Prevalent Resistance Genes**

Based on PubMed articles, the predominant antimicrobial resistance genes include:
- **qnrS** (quinolone resistance)
- **dfrA** (trimethoprim resistance)
- **sul** genes (sulfonamide resistance)
- **tet** genes (tetracycline resistance)
- **aadA** (aminoglycoside resistance)
- **blaCTX-M** and other beta-lactamase genes

([DOI](https://doi.org/10.1016/j.ijfoodmicro.2025.111578))

### **Serotype-Specific Patterns**

**Salmonella Infantis:**
- Emerging MDR clone with resistance to at least 5 antimicrobial families:
  - Ampicillin
  - Cephalosporins
  - Chloramphenicol
  - Nalidixic acid
  - Tetracycline
- Associated with megaplasmids carrying multiple resistance genes ([DOI](https://doi.org/10.1089/fpd.2024.0162))

**Salmonella Enteritidis and Typhimurium:**
- Among the most common serotypes with high MDR rates
- Frequently isolated from meat products ([DOI](https://doi.org/10.1016/j.foodres.2025.117918))

### **Key Transmission Mechanisms**

1. **Plasmid-mediated resistance**: IncX2, IncHI2, IncHI2A, IncC, IncR plasmids commonly carrying resistance genes ([DOI](https://doi.org/10.1016/j.ijfoodmicro.2025.111578))

2. **Chromosomal resistance regions**: Large chromosomal MDR regions (up to 58 kb) containing multiple resistance genes ([DOI](https://doi.org/10.1016/j.ijfoodmicro.2025.111578))

### **Geographic Trends**

- **Asia**: High MDR prevalence in China, Hong Kong, and Korea
- **Global dissemination**: Evidence of clonal spread between continents, particularly for S. Infantis strains with connections to North America, South America, and West Asia ([DOI](https://doi.org/10.1089/fpd.2024.0162))

## Public Health Implications

The research emphasizes that:
- Critical antibiotics for treating severe Salmonella infections (ciprofloxacin, ceftriaxone, azithromycin) are increasingly compromised
- Food chain contamination, particularly in pork, beef, and poultry, represents a major transmission route
- Enhanced surveillance and genomic monitoring are urgently needed to track emerging MDR strains

These patterns underscore the need for improved biosecurity measures, antimicrobial stewardship, and integrated One Health surveillance approaches to combat the rising threat of antimicrobial-resistant Salmonella.",,36.61733388900757,15,1529,12623,79383,"mcp__pubmed__search_articles, mcp__togomcp__search_mesh_descriptor, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""Salmonella antimicrobial resistance patterns prevalence"", ""max_results"": 20, ""sort"": ""pub_date""}}, {""name"": ""mcp__togomcp__search_mesh_descriptor"", ""input"": {""query"": ""Salmonella antimicrobial resistance"", ""limit"": 5}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41478103"", ""41508433"", ""41270449"", ""40014431"", ""41570997"", ""41546026"", ""41597711"", ""41525800""]}}]",VALUABLE,"Resistance profiles for Salmonella including resistance to ampicillin, tetracycline, and other common antibiotics from AMR Portal","COMPLEX QUERY requiring AMR Portal knowledge.

Databases/Resources: AMRPortal, NCBI Taxonomy

Knowledge Required:
- PhenotypeMeasurement for resistance test results
- GenotypeFeature for resistance genes/mutations
- Taxonomy filtering via obo:RO_0002162
- Two-stage aggregation for cross-database analytics
- Case-insensitive filtering for inconsistent text fields

Without proper knowledge: Cannot correlate genotype-phenotype data or filter by organism.

Verified in amrportal_exploration.md (Surveillance Analysis Patterns)."
35,2026-02-01,Precision,What is the ClinVar accession for the common cystic fibrosis variant p.Phe508del?,True,True,False,0.0,"The ClinVar accession for the common cystic fibrosis variant p.Phe508del (also known as F508del or ΔF508) is **RCV000000138**.

This variant, which involves a deletion of phenylalanine at position 508 in the CFTR protein, is the most common pathogenic variant causing cystic fibrosis, accounting for approximately 70% of CF alleles worldwide. It is classified as pathogenic in ClinVar.",,3.555986166000366,63,112,True,False,0.0,"The ClinVar accession for the common cystic fibrosis variant p.Phe508del is **VCV004072070** (version VCV004072070.1).

This variant is:
- **Gene**: CFTR (cystic fibrosis transmembrane conductance regulator)
- **DNA change**: c.1522_1524del (deletion of nucleotides 1522-1524 in NM_000492.4)
- **Protein change**: p.Phe508del (deletion of phenylalanine at position 508)
- **Classification**: Pathogenic
- **Location**: Chromosome 7q31.2 (GRCh38: chr7:117559593-117559595)
- **Type**: In-frame deletion

This is indeed the most common disease-causing mutation in cystic fibrosis, accounting for approximately 70% of CF alleles worldwide.",,17.756869077682495,14,465,2035,78900,"mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary","[{""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""p.Phe508del cystic fibrosis"", ""max_results"": 10}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""clinvar"", ""ids"": [""4072070""]}}]",VALUABLE,VCV000007105,"SIMPLE QUERY - Straightforward variant lookup.

Method: bif:contains search in ClinVar for 'CFTR Phe508del'

Demonstrates when basic ClinVar search approaches suffice.

Verified in clinvar_exploration.md simple queries section."
36,2026-02-01,Precision,What glycosylation sites are known for human immunoglobulin proteins?,True,True,True,0.5555555555555556,"Human immunoglobulin proteins have several well-characterized glycosylation sites:

## IgG (most studied)
- **Conserved N-glycosylation site**: Asn297 (Asn-X-Ser/Thr motif) in the CH2 domain of the Fc region
- This is present in all four IgG subclasses (IgG1, IgG2, IgG3, IgG4)
- Critical for Fc effector functions (ADCC, CDC, complement activation)
- Typically contains complex-type biantennary glycans

**Variable region glycosylation**: 
- Found in approximately 15-25% of IgGs
- Sites vary depending on the specific antibody sequence
- Can occur in both heavy and light chains

## IgA
- **Heavy chain**: 2 N-glycosylation sites in the CH2 and CH3 domains (typically Asn263 and Asn459 in IgA1 numbering)
- **IgA1 specific**: O-glycosylation sites in the hinge region (up to 5 O-linked glycans on Ser/Thr residues)
- **J-chain**: Additional N-glycosylation site when present in polymeric forms

## IgM
- **Five N-glycosylation sites** per heavy chain (in Cμ2, Cμ3, and Cμ4 domains)
- Highly glycosylated compared to other immunoglobulins
- J-chain glycosylation in pentameric form

## IgE
- **Seven N-glycosylation sites** per heavy chain
- Most heavily glycosylated immunoglobulin class

## IgD
- Multiple N-glycosylation sites, though less well-characterized than other classes

The glycosylation patterns can affect antibody stability, effector functions, serum half-life, and immunogenicity.",,11.189819097518921,54,465,True,True,0.6666666666666666,"Based on my research using multiple biological databases, I can provide you with comprehensive information about glycosylation sites in human immunoglobulin proteins.

## Glycosylation Sites in Human Immunoglobulin Proteins

### **Fc Region Glycosylation (Conserved N-Glycosylation)**

According to PubMed, the most well-characterized and functionally important glycosylation site in human immunoglobulins is:

**Asn297 (Asparagine 297)** - This is a **conserved N-glycosylation site** located in the Fc (Fragment crystallizable) region of IgG antibodies. This site is present in the CH2 domain of the heavy chain constant region.

#### Key Features of Asn297 Glycosylation:

1. **Structure**: Asn297 typically bears complex-type N-glycans, predominantly bi-antennary structures ([DOI: 10.3389/fimmu.2023.1188838](https://doi.org/10.3389/fimmu.2023.1188838))

2. **Functional Significance**: 
   - Critical for antibody effector functions including:
     - **ADCC** (Antibody-Dependent Cellular Cytotoxicity)
     - **CDC** (Complement-Dependent Cytotoxicity)
   - Affects antibody secretion, structure, stability, and half-life
   - Maintains the integrity of the quaternary structure required for interaction with Fc receptors (FcγRs)
   ([DOI: 10.1016/j.biotechadv.2023.108201](https://doi.org/10.1016/j.biotechadv.2023.108201))

3. **Glycan Variations**: The oligosaccharide composition can vary by:
   - **Fucosylation**: Affects binding to FcγRIIIa
   - **Galactosylation**: Influences CDC activity
   - **Sialylation**: Associated with anti-inflammatory properties
   - **Bisecting GlcNAc**: Enhances ADCC
   - **Mannosylation**: Different functional profiles
   ([DOI: 10.1093/glycob/cwab064](https://doi.org/10.1093/glycob/cwab064))

### **Variable Domain Glycosylation (VDG)**

According to PubMed, in addition to the conserved Fc glycosylation, immunoglobulins can have **N-glycosylation sites in their variable domains** (Fab region). This is less common but clinically significant:

- **Location**: Found in the antigen-binding variable regions (VH and VL domains)
- **Prevalence**: Present in 15-25% of IgG antibodies in healthy individuals, but significantly enriched in:
  - Autoantibodies (especially in rheumatoid arthritis)
  - B-cell malignancies (follicular lymphoma)
  
- **Functions**:
  - Influences antigen binding affinity
  - Enhances antibody stability
  - Modulates interactions with neonatal Fc receptor (FcRn)
  - Can affect B-cell receptor (BCR) activation
  
- **Clinical Relevance**: VDG levels correlate with disease progression and therapeutic outcomes in autoimmune diseases
([DOI: 10.1016/j.smim.2025.101946](https://doi.org/10.1016/j.smim.2025.101946))

### **IgE-Specific Glycosylation**

IgE has additional N-glycosylation sites in its Fc region (Cε domains), though the Fc region of IgE differs structurally from IgG.

### **O-Glycosylation Sites**

Some immunoglobulin fusion proteins and therapeutic antibodies can have **O-glycosylation sites**. For example, etanercept (an Fc-fusion protein) contains 26 O-glycosylation sites with predominantly Core1 and Core2 O-glycan structures ([DOI: 10.1016/j.jpba.2025.117326](https://doi.org/10.1016/j.jpba.2025.117326)).

### **Summary Table**

| Location | Site | Type | Frequency | Function |
|----------|------|------|-----------|----------|
| IgG Fc (CH2) | Asn297 | N-glycan | 100% (conserved) | Effector functions, stability, half-life |
| Variable domains (Fab) | Variable positions | N-glycan | ~15-25% (higher in disease) | Antigen binding, stability, disease marker |
| IgE Fc | Multiple sites | N-glycan | Present | Receptor binding |
| Fusion proteins | Variable | O-glycan | Depends on protein | Stability, solubility |

The glycosylation of immunoglobulins, particularly at Asn297, is essential for proper immune function and is a critical consideration in the development of therapeutic antibodies.",,67.43379306793213,469,2526,24755,216195,"mcp__pubmed__search_articles, mcp__togomcp__search_uniprot_entity, mcp__ols__searchClasses, mcp__togomcp__run_sparql, mcp__pubmed__get_article_metadata, mcp__togomcp__run_sparql, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""human immunoglobulin glycosylation sites"", ""max_results"": 20}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""human immunoglobulin heavy chain"", ""limit"": 10}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""immunoglobulin glycosylation"", ""pageSize"": 10}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\n\nSELECT DISTINCT ?protein ?proteinName ?glycosite ?position ?comment\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:annotation ?annotation ;\n           up:recommendedName ?recName .\n  \n  ?recName up:fullName ?proteinName .\n  \n  ?annotation a up:Glycosylation_Annotation ;\n              up:range ?range .\n              \n  OPTIONAL { ?annotation rdfs:comment ?comment }\n  \n  ?range up:begin ?begin .\n  ?begin up:position ?position .\n  \n  BIND(?annotation as ?glycosite)\n  \n  FILTER(CONTAINS(LCASE(?proteinName), \""immunoglobulin\""))\n}\nLIMIT 100""}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41483721"", ""41381428"", ""41361570""]}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\n\nSELECT DISTINCT ?protein ?name ?annotation ?position ?description\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:recommendedName/up:fullName ?name ;\n           up:annotation ?annotation .\n  \n  ?annotation a up:Glycosylation_Annotation ;\n              rdfs:comment ?description ;\n              up:range/up:begin/up:position ?position .\n  \n  FILTER(CONTAINS(LCASE(?name), \""gamma\""))\n  FILTER(CONTAINS(LCASE(?name), \""heavy\""))\n}\nORDER BY ?name ?position\nLIMIT 50""}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""IgG N-glycosylation site Asn297"", ""max_results"": 10}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""37575234"", ""37336296"", ""34192331""]}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""immunoglobulin Fc glycosylation sites review"", ""max_results"": 15}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""40158366"", ""35562647"", ""30484251""]}}]",VALUABLE,N-linked and O-linked glycosylation sites on immunoglobulin proteins from GlyCosmos database,"COMPLEX QUERY requiring GlyCosmos structure knowledge.

Databases/Resources: GlyCosmos

Knowledge Required:
- Multi-graph architecture requiring FROM clause
- Glycoprotein → Glycosylation site relationship
- Human/organism filtering essential (414K+ total sites)
- Cross-references to UniProt via rdfs:seeAlso

Without proper knowledge: Query returns mixed organism results or times out.

Verified in glycosmos_exploration.md (Glycosylation Site Queries)."
